Arcus Biosciences nears key catalysts with late-stage assets & upcoming Phase 3 data. Discover potential upside & why it's ...

Compugen advances COM701 in ovarian cancer with strong partners, key catalysts ahead, and funding into 2027. Find out why ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

This study highlights CD229 as an immunotherapeutic target in multiple myeloma and demonstrates that dual-targeting chimeric antigen receptor T cells against CD229 and B-cell maturation antigen may ...

NK cells express inhibitory receptors (TIGIT, PD-1, NKG2A) that tumors exploit to evade immune attack, alongside activating receptors (NKG2D, DNAM-1) that promote cancer cell killing. Blocking ...

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s ...

It is no longer investing in the anti-TIGIT antibody belrestotug, which it was developing alongside iTeos Therapeutics. The pharma in May broke off its engagement with the Massachusetts-based biotech ...

Serious concerns have been raised over Smyth’s CD96 work, which formed the foundation for a cancer drug now being tested in humans.

Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for ...